M&A / Deals Gilead strikes again, penning $5bn deal to buy Tubulis PharmaphorumGilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaphorum Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront. M&A / DealsRead full story Post navigation Previous: AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat SolidifiesNext: 219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
